Rare, rarer, lung involvement in adult-onset Still's disease: A mini-review
Standard
Rare, rarer, lung involvement in adult-onset Still's disease: A mini-review. / Nies, Jasper F; Schneider, Udo; Krusche, Martin.
In: FRONT MED-LAUSANNE, Vol. 9, 989777, 16.09.2022.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Rare, rarer, lung involvement in adult-onset Still's disease: A mini-review
AU - Nies, Jasper F
AU - Schneider, Udo
AU - Krusche, Martin
N1 - Copyright © 2022 Nies, Schneider and Krusche.
PY - 2022/9/16
Y1 - 2022/9/16
N2 - Adult-onset Still's disease (AOSD) is a polygenic systemic autoinflammatory disease which is associated with increased morbidity and mortality. Pulmonary involvement is a rare, but serious complication of AOSD. As in AOSD, IL-1b, IL-18, and IL-6 dominate the molecular pathogenesis, which mediate a type 1 and type 3 inflammatory signature of the adaptive immune system. This is evidenced by the success of IL-1- and IL-6 inhibition in the management of AOSD. However, anaphylactic reactions to treatment with IL-1- or IL-6-inhibitors is currently being discussed as a potential trigger for lung involvement inf AOSD, while genetic risk factors have also been identified. Clinically, pulmonary involvement in AOSD can manifest in many different forms. Parenchymal inflammation with peripheral consolidations is the most frequent form while PAH is less common, but often very difficult to manage. This mini-review provides an overview of the pathophysiology as well as the clinical presentation and the diagnostic features of pulmonary involvement in AOSD.
AB - Adult-onset Still's disease (AOSD) is a polygenic systemic autoinflammatory disease which is associated with increased morbidity and mortality. Pulmonary involvement is a rare, but serious complication of AOSD. As in AOSD, IL-1b, IL-18, and IL-6 dominate the molecular pathogenesis, which mediate a type 1 and type 3 inflammatory signature of the adaptive immune system. This is evidenced by the success of IL-1- and IL-6 inhibition in the management of AOSD. However, anaphylactic reactions to treatment with IL-1- or IL-6-inhibitors is currently being discussed as a potential trigger for lung involvement inf AOSD, while genetic risk factors have also been identified. Clinically, pulmonary involvement in AOSD can manifest in many different forms. Parenchymal inflammation with peripheral consolidations is the most frequent form while PAH is less common, but often very difficult to manage. This mini-review provides an overview of the pathophysiology as well as the clinical presentation and the diagnostic features of pulmonary involvement in AOSD.
U2 - 10.3389/fmed.2022.989777
DO - 10.3389/fmed.2022.989777
M3 - SCORING: Review article
C2 - 36186767
VL - 9
JO - FRONT MED-LAUSANNE
JF - FRONT MED-LAUSANNE
SN - 2296-858X
M1 - 989777
ER -